Sign In
Buy AKBA
$0.97
+0.0333 (+3.56%)
At Close: Jun 03, 2026
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
07:00am, Monday, 10'th Nov 2025
Vafseo® (vadadustat) Q3 2025 net product revenues grew to $14.3 million ; Q3 2025 total net product revenues were $56.8 million Operational pilot of Vafseo at DaVita expected to complete in the fou
Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025 Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025
Akebia Therapeutics to Present at Upcoming Investor Conferences
08:00am, Tuesday, 04'th Nov 2025
CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 03'rd Nov 2025
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Ethic Inc. Has $148,000 Stock Position in Akebia Therapeutics, Inc. $AKBA
04:11am, Saturday, 01'st Nov 2025
Ethic Inc. boosted its holdings in shares of Akebia Therapeutics, Inc. (NASDAQ: AKBA) by 243.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securiti
Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights
08:00am, Thursday, 30'th Oct 2025
CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2025, on
FDA Pushback Prompts Akebia To Drop Broad Label Pursuit For Kidney Disease Drug
02:13pm, Wednesday, 29'th Oct 2025
Akebia Therapeutics Inc. (NASDAQ:AKBA) stock is trading lower on Wednesday.
Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients
04:30pm, Tuesday, 28'th Oct 2025
Akebia does not expect to initiate VALOR clinical trial following Type C meeting feedback from U.S. FDA Akebia does not expect to initiate VALOR clinical trial following Type C meeting feedback from U
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Consensus Rating of “Moderate Buy” from Brokerages
01:32am, Wednesday, 22'nd Oct 2025
Akebia Therapeutics, Inc. (NASDAQ: AKBA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seven analysts that are currently covering the firm, MarketBeat.com reports
Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025
08:08am, Monday, 20'th Oct 2025
Presentations Detail Ongoing Vafseo® (Vadadustat) Real-World Studies and Explore Insights Regarding Clinical Benefits and Dosing of Vafseo Presentations Detail Ongoing Vafseo® (Vadadustat) Real-Worl
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
12:01pm, Tuesday, 14'th Oct 2025
Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 01'st Oct 2025
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, g
Akebia Therapeutics, Inc. (AKBA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
01:34am, Friday, 05'th Sep 2025
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:00 AM EDT Company Participants Erik Ostrowski - Chief Business Officer, Senior VP, CFO &
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 02'nd Sep 2025
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease
Akebia Therapeutics: Post-Earnings Dip Looks Like A Discounted Entry Ahead Of A Vafseo Inflection
08:17am, Thursday, 28'th Aug 2025
I'm bullish on Akebia at $3.13, viewing the 21% post-earnings dip as a buying opportunity ahead of major revenue catalysts. Vafseo's rapid adoption and DaVita's pilot could double Akebia's addressable
